ESTERO, FL - Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) has submitted a Pre-Investigational New Drug (Pre-IND) meeting request to the U.S. Food and Drug Administration for its lead product ...
In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...
AUSTIN, Texas--(BUSINESS WIRE)--Mystic Pharmaceuticals, Inc. today announced the availability of its Javelin Sublingual™ drug delivery devices. Javelin Sublingual dispensers utilized Mystic’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback